Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419159 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT00419159 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 199 participants.
The verdict
NCT00419159, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.
Interventions
- DRUG Everolimus (RAD001)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419159
The ClinicalTrials.gov registry entry for NCT00419159 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus (RAD001) is the first listed.
NCT00419159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419159 about?
NCT00419159 is a clinical study titled "Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy". To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.
What is the current status of trial NCT00419159?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2006-12. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00419159?
The interventions under investigation include: Everolimus (RAD001) (DRUG).
Who is sponsoring clinical trial NCT00419159?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.